Antiplatelet

Is it Time to Give Up Aspirin after PCI in High Bleeding Risk Patients? A Critical Analysis of STOPDAPT-3

Short dual antiplatelet treatment (DAPT) has been adopted in high bleeding risk patients to minimize bleeding complications...

Dr. Juan Manuel Pérez - 27 May, 2025

Learn More

Acute coronary syndromes

EuroPCR 2025 | 4D-ACS Study: One-Month Dual Antiplatelet Therapy Followed by Low-Dose Prasugrel Monotherapy

While dual antiplatelet therapy (DAPT) has long been the standard treatment for managing patients with acute coronary...

Dr. Andrés Rodríguez - 26 May, 2025

Learn More

Antiplatelet

Cangrelor in Acute and Chronic Coronary Syndromes: The POMPEII Registry

Platelet inhibition during and after coronary angioplasty is essential to prevent peri- and post-procedural ischemic events. To...

Dr. Omar Tupayachi - 21 May, 2025

Learn More

Acute coronary syndromes

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary...

Dr. Omar Tupayachi - 29 April, 2025

Learn More

Antiplatelet

SMART-CHOICE 3 | Efficacy and Safety of Clopidogrel vs Aspirin Monotherapy in High Risk Patients after Percutaneous Coronary Intervention

Courtesy of Dr. Juan Manuel Pérez. After post percutaneous coronary intervention (PCI) standard duration dual antiplatelet therapy (DAPT),...

Dr. Juan Manuel Pérez - 14 April, 2025

Learn More

Antiplatelet

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a...

Dr. Andrés Rodríguez - 8 April, 2025

Learn More

Antiplatelet

Ultrathin vs Thin-Strut Stents in PCI Patients at High Bleeding Risk

Several in vivo studies have shown that ultrathin stents present lower thrombogenic risk vs. thin-strut stents, which...

Dr. Andrés Rodríguez - 10 October, 2024

Learn More

Antiplatelet

ESC 2024 | QUADRO Trial: Efficacy and Safety of the First Quadruple Therapy Single Pill in Resistant Hypertension Patients

Researchers conducted an international, randomized, parallel-group study with a superiority design over a 16-week period. The doses...

Dr. Omar Tupayachi - 5 September, 2024

Learn More

Antiplatelet

Is it Time to Give Up Aspirin after PCI in High Bleeding Risk Patients? A Critical Analysis of STOPDAPT-3

EuroPCR 2025 | 4D-ACS Study: One-Month Dual Antiplatelet Therapy Followed by Low-Dose Prasugrel Monotherapy

Cangrelor in Acute and Chronic Coronary Syndromes: The POMPEII Registry

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

SMART-CHOICE 3 | Efficacy and Safety of Clopidogrel vs Aspirin Monotherapy in High Risk Patients after Percutaneous Coronary Intervention

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Ultrathin vs Thin-Strut Stents in PCI Patients at High Bleeding Risk

ESC 2024 | QUADRO Trial: Efficacy and Safety of the First Quadruple Therapy Single Pill in Resistant Hypertension Patients

Last News

Coronary Perforations and Use of Covered Stents: Safe and Effective Long-Term Strategy?

Is it really necessary to monitor all patients after TAVR?

Is it really necessary to monitor all patients after TAVR?

Institutional News

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

Watch Again: SELUTION – Sirolimus-Eluting Balloon for De Novo Coronary Lesions – New Evidence and Clinical Perspectives

25/11 – SOLACI Webinar: Pulmonary Embolism in 2025 – Risk Stratification and Novel Therapeutic Approaches

Access